You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
A new study supports the development of BET inhibitors for MYCN-driven triple negative breast cancer as a single agent and in combination with a MEK inhibitor.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.